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The aetiology of Parkinson’s disease (PD) is yet to be fully understood but it is becoming more and more evident that neuronal
cell death may be multifactorial in essence. The main focus of PD research is to better understand substantia nigra homeostasis
disruption, particularly in relation to the wide-spread deposition of the aberrant protein α-synuclein. Microarray technology
contributed towards PD research with several studies to date and one gene, ALDH1A1 (Aldehyde dehydrogenase 1 family, member
A1), consistently reappeared across studies including the present study, highlighting dopamine (DA) metabolism dysfunction
resulting in oxidative stress and most probably leading to neuronal cell death. Neuronal cell death leads to increased inflammation
through the activation of astrocytes and microglia. Using our dataset, we aimed to isolate some of these pathways so to oﬀer
potential novel neuroprotective therapeutic avenues. To that eﬀect our study has focused on the upregulation of P2X7 (purinergic
receptor P2X, ligand-gated ion channel, 7) receptor pathway (microglial activation) and on the NOS3 (nitric oxide synthase 3)
pathway (angiogenesis). In summary, although the exact initiator of striatal DA neuronal cell death remains to be determined,
based on our analysis, this event does not remain without consequence. Extracellular ATP and reactive astrocytes appear to
be responsible for the activation of microglia which in turn release proinflammatory cytokines contributing further to the
parkinsonian condition. In addition to tackling oxidative stress pathways we also suggest to reduce microglial and endothelial
activation to support neuronal outgrowth.
1. Introduction
Parkinson’s disease (PD), estimated to aﬀect 1-2% in the
population over the age of 65, rises to 3–5% in people over
85 years of age since age is a predisposing factor [1, 2]. Clin-
ically PD symptomology includes both motor and nonmotor
manifestations [3]. The cardinal motor symptoms are rigid-
ity, bradykinesia, resting or postural tremor, and postural in-
stability [4]. Nonmotor features include olfactory dysfunc-
tion, autonomic dysfunctions, for example, bladder dys-
function, constipation, and neuropsychiatric disturbances,
for example, sleep disorders, hallucinations, dementia, and
depression [5, 6]. The onset of motor deficits is primarily due
to the neurodegeneration of dopaminergic neurones that
originate in the substantia nigra pars compacta (SNpc) and
terminate in the caudate and putamen. It is estimated that
70% to 80% of striatal DA neurones are lost at the time of
first diagnosis of the motor symptoms [7]. Dopaminergic re-
placement strategies in the form of L-DOPA or dopamine ag-
onists form the principal strategies for treating PD but such
therapeutic approaches are often associated with long-term
loss of eﬃcacy and development of major side eﬀects [8].
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The aetiology of PD has yet to be fully understood but
it is becoming more and more evident that neuronal cell
death is a result of not just one event and that PD may be
multifactorial in essence supporting a “multiple hit” hypoth-
esis of neurodegeneration [9, 10]. Several events leading to
neuronal cell death have been isolated; however the sequence
of order in which these events occur remains to be deter-
mined. A consensus is emerging suggesting that the crossing
of a gene-environment susceptibility threshold yet to be de-
fined is responsible for initiating a cascade of several events
such as excitotoxicity, oxidative stress, inflammation, protein
aggregation, phagocytosis, and mitochondrial dysfunction
leading to apoptosis and that these diﬀerent factors might
present a degree of variation in weight dynamics across pa-
tients [8, 11].
Microarray gene expression profiling experiments have
increased our understanding of molecular pathogenic mech-
anisms involved in sporadic and familial PD providing new
avenues for research. Several microarray studies have been
carried out to date and have established transcriptome
profiles of the substantia nigra [12–18]. Most studies were
whole-tissue based except for one which was conducted ex-
clusively on dopaminergic neurones isolated from post-
mortem tissue by laser capture [18]. Additionally, most
studies have utilised the Aﬀymetrix platform array, except for
Bossers et al. (Agilent platform array) [16]. Furthermore, two
microarray studies have been conducted on blood samples
[19, 20]. Finally, a genomewide meta-analysis of gene sets
from the global PD gene expression (GPEX) consortium
highlighted novel underexpressed pathways involved in the
control of cellular bioenergetics in PD [21]. High throughput
whole-genome platforms are data-driven approaches and
assume no a priory aetiological hypothesis. We have recently
performed a gene expression analysis on RNA extracted from
the substantia nigra (SN) dissected from snap frozen tissues
from 12 neuropathologically confirmed cases of sporadic PD
and from 7 controls with no neurological disorders utilising
for the first time the Illumina whole-genomeHumanRef8 v2-
long-oligonucleotide microarray technology. This study was
part of large-scale microarray study of neurodegeneration
including several neurodegenerative diseases (manuscript
submitted by Durrenberger et al). We had tested several
platforms prior adopting the Illumina platform for its
advantageous eﬃciency over 100 genes (unpublished data).
Our main aim was to identify potential pathogenic pathways
responsible for the neuronal cell loss using microarray
technology. A better understanding of neurodegenerative
mechanisms could lead to new cellular andmolecular targets,
which, in turn, may permit the development of more
eﬀective and safe therapies. One of the main findings was
the detection of numerous significant upregulated genes
involved in immune response and inflammatory processes,
which will be the focus of this paper.
2. Materials and Methods
2.1. Tissue Samples. SNpc sample from 12 clinically and
neuropathologically diagnosed patients with idiopathic
Parkinson’s disease and 7 cases with no neurological con-
ditions were obtained from the Parkinson’s UK Tissue
Bank at Imperial College London and from the Wu¨rzburg
Brain Bank Centre in Germany. PD cases were chosen for
presenting an early-stage disease (Braak stage 4) rather than
end stage. Fully informed consent and ethical approval was
obtained for the collection and study of postmortem tissue
following guidelines recently published by the consortium
[22]. Both tissue banks are members of BrainNet Europe
Brain Bank Consortium Network (http://www.brainnet-
europe.org/). The tissue samples were snap-frozen as small
blocks in isopentane on dry ice. Basic details of the cases are
provided in Table 1.
2.2. Total RNA Extraction. Total RNA was extracted from
dissected snap-frozen tissue (<100mg) using the RNeasy
tissue lipid mini kit according to the manufacturer’s instruc-
tions (Qiagen Ltd, Crawley, UK) and stored at −80◦C until
further use. RNA concentration and purity was assessed
by spectrophotometry (NanoDrop ND1000; NanoDrop
Technologies, Delaware, USA). RNA integrity was further
assessed using an Agilent 2100 Bioanalyzer and its lab-on-
a-chip platform technology (Agilent Technologies UK Ltd,
West Lothian, UK). This system integrates several features
in addition to the 28S/18S ribosomal ratio to determine
a final RNA integrity number (RIN) [23]. Our samples
presented an average RIN value of 6.69 ± 0.6. Homogeneity
of RNA quality across samples is crucial for eﬀective results
of microarray experiments which are entirely dependent on
the quality of RNA [24].
2.3. Microarray Experiment and Analysis. Gene expression
analysis was performed on RNA extracted from snap-
frozen tissues with the Illumina whole-genome HumanRef8
v2 BeadChip (Illumina, London, UK). All samples were
analysed on the same day under identical conditions. RNA
samples were prepared for array analysis using the Illumina
TotalPrep-96 RNA Amplification Kit and following the
manufacturer’s instructions (Ambion/Applied Biosystems,
Warrington, UK). First and second strand cDNA was
synthesised from 0.5 μg of total RNA and labelled with
biotin. The biotin-labelled cRNA were applied to the arrays
using the whole-genome gene expression direct hybridis-
ation assay system from Illumina. Finally the BeadChips
were scanned using the Illumina BeadArray Reader. The
data was extracted using BeadStudio 3.2 (Illumina, London,
UK). Data normalisation and gene diﬀerential analysis was
conducted using the Rosetta error models available in the
Rosetta Resolver system (Rosetta Biosoftware, Seattle, WA,
USA) [25]. Fold changes and P values were generated based
on an intensity ratio between control and disease using a
conversion pipeline provided by Rosetta.Multiple testing was
carried out to eliminate false positives. Intensity values of
individual genes will be presented nonconverted. A principal
component analysis was first carried out to detect low quality
arrays and a cluster analysis (P < 0.01) using a hierarchical
algorithm (agglomerative) was conducted to detect potential
outliers. No low quality arrays or outliers were detected for
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Table 1: Basic clinical and neuropathological characteristics of study cases.
Case Gender
Age at Death
(years)
Illness Duration
(years)
PM delay
(hours)
COD
C01 M 66 N/A 23.00 Global heart failure, hypopharynx carcinoma
C02 M 54 N/A 27.00 Pneumonia, respiratory failure
C03 M 64 N/A 50.00 Kearns-Sayre-Syndrome, resp. failure
C04 M 55 N/A 24.00 Aspiration pneumonia
C05 F 60 N/A 9.00
Circulatory collapse, cutaneous T-cell-lymphoma perianal
carcinoma
C06 M 58 N/A 9.00 Unknown
C07 F 104 N/A 9.50 Chest infection
Mean value 64.5± 5.85 27.94± 4.84
PD01 F 86 15 5.50 Sudden collapse
PD02 M 78 24 20.25 Unknown
PD03 F 85 18 13.50 Bronchopneumonia, Breast Cancer with metastasis and PD
PD04 F 76 10 13.50 Unknown
PD05 M 77 10 5.50 Unknown
PD06 M 80 19 16.00 Unknown
PD07 M 80 5 7.00 Unknown
PD08 F 80 13 10.00 Old age and PD
PD09 M 86 8 2.50 Ischaemic bowel and atrial fibrillation
PD10 F 87 9 22.00 Gastrointestinal bleeding
PD11 F 81 14 21.50 Unknown
PD12 M 82 11 10.00
Pneumonia, Fractured neck of femur, Pulmonary embolisms,
COPD, Dementia
Mean value 81.5± 1.07 13± 1.54 12.2± 1.91
C: Control; PD: Parkinson’s disease; PM: Postmortem; COD: cause of death.
the PD cohort. Gene lists containing statistically significant
(P < 0.01) diﬀerentially expressed genes were generated.
Significant dysregulated genes with fold change superior or
equal to 1.5 were given priority. A gene set enrichment
analysis (GSEA) was also conducted (enrichment algorithm:
Mann-whitney U-Test; P < 0.05) on all, upregulated and
downregulated genes to determine main biological processes
and main up- and downregulated biological processes.
Pathway Studio software (Ariadne Genomics Inc., Madrid,
Spain) was used to assist with biological interpretation.
2.4. Quantification of mRNA Expression by RT-qPCR. The
two-step real-time reverse transcriptase quantitative poly-
merase chain reaction (RT-qPCR) was performed using the
QuantiTect reverse transcription kit, the QuantiTect SYBR
Green kit and with QuantiTect primer assays (Qiagen) as
previously described [26]. Briefly, real-time PCR experi-
ments were performed using the Mx3000P real-time PCR
systemwith software version 4.01 (Stratagene, La Jolla, USA).
The QuantiTect primer assays are listed in Table 3. For each
sample, reactions were set up in duplicate with the following
cycling protocol, 95◦C for 15min, 40 cycles with a 3-step
program (94◦C for 15 s, 55◦C for 30 s, and 72◦C for 30 s)
and a final melting curve analysis with a ramp from 55
to 95◦C. Expression levels of target genes were normalised
to the levels of the BECN1 reference gene and calibrated
utilising a standard curve method for quantitation. Beclin-
1 was found as the most stable gene amongst the most
commonly used reference genes [26] and was hence used
as our main normaliser. Some results were duplicated using
XPNPEP1, a novel reference gene determined from our
main experimental study of neurodegeneration (paper in
preparation).
2.5. Statistical Analysis. The following software packages
were used GraphPad Prism 5.01 (GraphPad Software Inc, La
Jolla, CA, USA) and Microsoft Oﬃce Excel 2007 (Microsoft
UK Headquarters, Reading, UK). Group diﬀerence was
established using Rosetta Resolver system for the microarray
data and/or a Student t-test (2-tailed or 1-tailed whenever
appropriate). The Pearson correlation test was used to
establish a relationship between 2 variables. Homogeneity of
variance was established with the F test. Fisher’s exact test was
used as a nonparametric test to compare gender. Diﬀerences
were considered statistically significant if the P value was
<0.05.
3. Results
3.1. Microarray Data Analysis. Genes of low intensity (<30
signal-intensity-based and with signal P > 0.05) were
not considered. In addition to the Rosetta error model,
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Table 2: List of top 20 biological processes for all, up- and downregulated genes (P < 0.005).
knaR
noissimsnartcitpanySnoitalucricdoolBnoissimsnartcitpanyS1
tropsnartnoInoisehdallec-llectnednepedni-muiclaCtropsnartnoI2
3 Nervous system development Immune response
Gamma-aminobutyric acid
signaling pathway
tnempolevedmetsyssuovreNssecorpcitehtnysoibeneirtokueLnoisehdalleC4
noitercesrettimsnartorueNsisenegoignAtropsnartnoitaC5
6 Gamma-aminobutyric acid signaling pathway
Antigen processing and presentation of peptide
or polysaccharide antigen via MHC class II
Neurotransmitter transport
noitpecrepyrosneSesnopserenummidetaidemnilubolgonummItropsnartnoimuiclaC7
8 Neurotransmitter transport
Antigen processing and presentation of
exogenous peptide antigen via MHC class II
Cation transport
9 Intracellular signaling cascade Leukotriene metabolic process
Regulation of membrane
potential
10 Negative regulation of signal transduction Cytoskeleton organization and biogenesis
Negative regulation of signal
transduction
11
antigen processing and presentation of
exogenous peptide antigen via MHC class II
tropsnartnegyxOnoisehdalleC
sisotycoxefonoitalugeResnopseryrotammaflnIsisenegoignA21
13 Calcium ion-dependent exocytosis Oligopeptide transport
Calcium ion-dependent
exocytosis
roivahebyrotomocoLhtworglleCesnopseryrotammaflnI41
15 Blood circulation
Positive regulation ofi nterleukin-1 beta
secretion
Dopamine metabolic process
tropsnartnoimuiclaCtnempolevedniarBnoisehdallec-llectnednepedni-muiclaC61
sixatomehCssecorpcilobatemdicaonimAsixatomehC71
ecnatsbuscinagrootesnopseRsixatomehclihportueN81
Dopamine receptor signaling
pathway
19 Regulation of exocytosis Arachidonic acid metabolic process Inner ear development
sixatomehclihportueNesnopserenummI02
Regulation of dopamine
secretion
all genes Up regulated Down regulated
Colours are respectively similar between all genes list to either up- or downregulated genes. Blue/green shades for downregulated; Red/yellow shadesfor
upregulated.
a Student t-test (2-tailed; 2-sample unequal variance) was
conducted on each gene. A total of 1,423 genes remained
(808 upregulated and 615 downregulated) with a greater than
1.5 fold change. The full list can be found in Supplemental
1 of the supplementary material available on line at doi:
10.1155/2012/214714. The gene set enrichment analysis
(GSEA) determined most representative biological processes
for all genes and for up- and downregulated genes. The main
upregulated biological processes were related to immune
response and angiogenesis, while neuronal related pro-
cesses were clearly shown to be downregulated as expected
(Table 2).
3.2. RT-qPCR Confirmation. To confirm some findings from
the microarray data, we successfully replicated expression
levels from 33 genes using RT-qPCR. Microarray fold
changes and P values (Rosetta Resolver system and Students
t-test), qPCR fold changes (expression ratio between the
2 groups), qPCR P value (Student t-test), and correlation
(Pearson) results between microarray and qPCR for each
gene are shown in Table 3. Altogether, a good significant
correlation between the fold changes from both hybridis-
ation experiments on the 33 genes investigated was found
(Figure 1). Only on 2 occasions, expression levels between
both experiments did not correlate. Three PD cases showed
higher levels of TNFRSF14 (Tumour necrosis factor receptor
superfamily, member 14) with qPCR than with the microar-
ray study. Similarly 2 PD cases showed higher levels of ELF1
(E74-like factor 1) with qPCR than with the microarray
study. Once removed the correlation was significant (data not
shown).
3.3. Cross-Study Comparative Analysis. To further validate
our data we compared our list of other published microarray
datasets available in the public domain. Firstly, we cross-
referenced our gene list with the most recent microarray
study which was also carried out on a 60-mer oligonucleotide
array but using the Agilent platform [16]. Altogether, 66%
of the genes from Bossers et al. (124 genes out of a total of
288 represented on both platforms) were also significantly
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Figure 1: Fold change comparison between the 2 hybridisation
techniques. Expression levels from the microarray data of 33 genes
were replicated successfully using RT-qPCR. We compared fold
changes generated by both hybridisation techniques, conducted a
correlation test and found to be a good concordance in expression
levels on those 33 genes (r2 = 0.8744; P < 0.0001).
dysregulated in similar fashion as in our dataset (Figure 2(a))
and there was a good concordance based on fold changes over
the 124 genes (r2 = 0.634; P < 0.001; XY pairs = 124) with
perhaps on occasions higher fold changes reported with the
Illumina platform (Figure 2(b)).
Using an available software tool provided by the Eskitis
Institute for Cell and Molecular Therapies, Griﬃth Uni-
versity (http://ncascr.griﬃth.edu.au/) containing a reanalysis
with diﬀerentially expressed gene lists for several studies,
we then cross-referenced expression levels of the genes from
the Illumina output with 8 gene lists generated from 7
available independent studies at P < 0.05 using only the
Aﬀymetrix platform [27]. Other microarrays studies have
been conducted in PD which were not available within
this software tool [21]. Out of 1,423 genes from our list,
approximately 40% were significantly dysregulated in at
least in one other microarray study. Twelve genes con-
sistently reappeared to be significantly dysregulated across
studies (Table 4 and Supplemental 2 ). ALDH1A1, AGTR1
(angiotensin II receptor, type 1), ANK1 (ankyrin 1), ATP8A2
(ATPase, aminophospholipid transporter-like, Class I, type
8A), and CBLN1 (Cerebellin 1 precursor) were the most
consistently reported downregulated gene across studies.
These 5 genes suggest deficiencies in oxidation reduction,
regulation of vasoconstriction, cytoskeleton organisation
(most likely underlying cell proliferation), ATP biosyn-
thetic process, and synaptic transmission (resp.). ALDH1A1
was consistently (7/8 lists) reported downregulated across
microarray studies including ours, that is, various platforms,
highlighting dysfunction in DA metabolism but comments
on explaining its exact implication in the parkinsonian brain
124 genes
P < 0.05
Illumina Agilent
(a)
Il
lu
m
in
a
Agilent
r2 = 0.634
P < 0.0001
4
3
2
1
−1
−2
−3
−4
−5
−6
−7
−8
−1 1 2 3
XY pairs = 124
(b)
Figure 2: Comparison with Agilent platform. We conducted a
direct comparison with the most recent microarray study which
was also carried out on a 60-mer oligonucleotide array but using
the Agilent platform [16]. 66% of the genes from Bossers et al. (124
genes out of 288 found in represented on both platforms) were also
significantly dysregulated in similar fashion as in our dataset (a) and
there was a good concordance based on fold changes over the 124
genes (r2 = 0.634; P < 0.001; XY pairs = 124; b).
remained inconclusive. Using a pathway analysis software
(Pathway studio), we established directly link genes from our
dataset with ALDH1A1 and its pathway will be discussed
thereafter (Figure 3).
3.4. Inflammatory Pathway. A very strong significant im-
mune-related component was detected by our dataset with
the upregulation of numerous immune-related genes cov-
ering several categories such as immune or inflammation
response, antigen or leukotriene processing, cell proliferation
or expansion, and cell adhesion just to mention a few
(Table 2). More than 40 genes were found from our list
belonging to the category “immune and inflammatory
response” just alone. To those we can add several others
involved in cell adhesion or proliferation such as integrins.
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Figure 3: ALDH1A1 pathway. This graph shows all genes from our dataset (except SNCA) known to interact with ALDH1A1. In blue
represent genes that are downregulated, in yellow genes that are upregulated and in grey genes not significantly dysregulated but important
for the pathway. Line in purple represent binding between two molecules and an arrow with a positive sign represent a positive regulation.
Furthermore, inflammatory response goes hand in hand
with angiogenesis since angiogenesis is triggered by hypoxia
and inflammation [28]. Two main pathways will be dis-
cussed, P2X7 receptor (P2RX7) and nitric oxide synthase
3 (NOS3). Using Pathways Studio, we established directly
interacting genes from our dataset with NOS3 (Figure 4).
We have selected to comment on only a selection, mostly on
eﬀector molecules or receptors, as they might have potential
direct immunomodulatory therapeutic value. P2RX7 and
NOS3 increases have both been demonstrated by both
expression-profiling techniques (Table 3). In addition two
other immune-related genes, TNFRSF14 and CBLN1, will be
discussed in relation to nervous system development.
4. Discussion
One of ourmain finding was that immune-related genes were
strongly significantly upregulated and were predominant
compared to genes of other functions. Two pathways were
isolated and will be discussed; P2RX7 and NOS3 and two
additional genes will be commented on: TNFSFR14 and
CBLN1. Several microarray studies on parkinsonian sub-
stantia nigra have been conducted over the last 7 years
using mainly the aﬀymetrix platform. The present study
was part of large-scale analysis of genomewide changes
in neurodegenerative diseases. The Illumina platform was
selected over others for being quality and cost-eﬀective. We
placed our gene list in context with some other published
gene lists from several independentmicroarray studies on the
substantia nigra to determine concordance levels as well as to
determine the most important pathway in the parkinsonian
substantia nigra across studies. Our study was the first to
our knowledge to use the Illumina platform to investigate
abnormal pathways in the parkinsonian brain. Our dataset
showed most similarities with the Agilent platform, another
60-mer oligonucleotide array [16] and ALDH1A1 was most
represented across microarray studies [27].
4.1. Aldh1a1, Dopamine Metabolism, and Oxidative Stress.
Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1)
was consistently reported downregulated across microar-
ray studies including ours (Table 4); however its exact
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Figure 4: NOS3 pathway. This shows all genes from our dataset (except SNCA) known to interact with ALDH1A1. In blue represent genes
that are downregulated and in yellow genes that are upregulated. Line in purple represent binding between two molecules and an arrow with
a positive sign represent a positive regulation.
implication in the parkinsonian brain remains to be fully
comprehended. ALDH1A1 downregulation was mentioned
first by Grunblatt et al. [17] and was more comprehensively
discussed in Mandel et al. [29]. The Aldehyde dehydrogenase
superfamily has recently been extensively reviewed [30]. This
cytosolic isoenzyme is ubiquitously expressed in various
tissues and in the brain it is highly expressed in dopaminergic
neurones of the substantia nigra [31]. It is suggested that
Aldh1a1 maintains reduced intraneuronal levels of DOPAL
(3,4-dihydroxyphenylacetaldehyde) by catalysing its metab-
olism to 3,4-dihydroxyphenylacetic acid (DOPAC). This
homeostatic function is crucial since evidence showed that
accumulation of DOPAL may be neurotoxic and may result
in neuronal cell death [32]. Decreased levels of ALDH1A1
have not been reported in the peripheral blood initially [20]
but in another study ALDH1A1 was reported as being part
of a combination of four genes having potential diagnostic
value to detect individuals at risk of developing PD [33].
ALDH1A1 is under the transcriptional control of paired-
like homeodomain 3, PITX3 [34] which is also significantly
downregulated in our dataset (fold change: x-2.13, Figure 3).
Loss of Pitx3 has been directly linked to selective loss of
neurones in the SNpc [35]. Furthermore, Pitx3 is directly
linked to dopamine metabolism since Pitx3 was found to
regulate tyrosine hydroxylase [36]. Other genes associated
with dopamine metabolism were also found downregulated
which have been previously reported. These include tyrosine
hydroxylase (TH; x-3.1), nuclear receptor subfamily 4,
group A, member 2 (NR4A2 formerly known as Nurr1; x-
2.96), dopamine receptor D2 (DRD2; x-2.95), solute carrier
family 6 (neurotransmitter transporter, dopamine), member
3 (SLC6A3 aka DAT; x-4.1), and solute carrier family 18
(vesicular monoamine), member 2 (SLC18A2 aka VMAT2;
x-5.65).
Decreases in gene expression of specific neuronal related
genes could be due to the dramatic loss of neurones observed
in the substantia nigra. The loss of dopaminergic neurones
is estimated to be around 80% [9]. One study, however,
estimated that neuronal loss in PD decreased only by 29%.
This study showed that neuromelanin-containing neurones
sustained most of the loss (51%) while non-neuromelanin-
containing neurones increased surprisingly by 104% in PD
levelling the loss of total neurones to 29% [16]. The authors
consequently suggested that observed decreases of gene
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Figure 5: Summary of P2X7 receptor microglial activation.
Schematic representation of microglial activation via the P2X7
receptor by extracellular ATP or interferon-γ (IFN-γ) resulting in
the release of tumour necrosis-α (TNF-α), CC-chemokine ligand 3
(CCL-3), superoxide (SO), nitric oxide (NO), and interleukin-1β
(IL1-β) by microglia. Central picture provided by Durrenberger.
expression above 29% in neuronal associated genes could not
be accounted solely to neuronal cell loss. Their assumption
however is based on the assumption of a linear relationship
between gene product and cell number. Only further in
vitro and in vivo studies will help to better understand
the ratio between gene products and cell number including
compensatory mechanisms.
4.2. P2RX7 Pathway and Microglial Activation. We observed
increased P2RX7 mRNA levels in PD substantia nigra
and confirmed expression levels with RT-qPCR. The P2X
ionotropic receptors are ATP-gated ion channels and
responds to extracellular ATP [37]. ATP is usually released
from damaged cells as a result of oxidative stress (as dis-
cussed above), ischemia, or inflammation [38]. For instance,
astrocytes communicate with Ca2+ waves in situation of
brain damage or insult with concomitant ATP release and
consequently activate microglial purinergic receptors [39].
Purinergic signalling has recently extensively been reviewed
[40–42]. Expressed highly on cells of monocyte/macrophage
lineage (but also on neurones and astrocytes), once acti-
vated, multiple intracellular signalling pathway follows
in microglial cells and consequently the release of pro-
inflammatory cytokines and chemokines such as tumour
necrosis factor-α (TNF-α) [43], interleukin-1β (IL-1β) [44],
CC-chemokine ligand 3 [45] and the production of super-
oxide [46], and nitric oxide [47] (summary can be found in
Figure 5). Although, studies on postmortem SN tissue and
cerebrospinal fluid support elevated levels of inflammatory
cytokines such as TNF, IL1β, IL-2, IL-4, and IL-6 [48–
50], a direct link between microglial activation and PD
disease outcome as yet to be determined [51]. However, in
vivo imaging of microglial activation with the peripheral
benzodiazepine receptor binding ligand [11C]-(R) PK11195
in positron emission tomography (PET) scans would suggest
an early role of microglia in disease [52]. It is also suggested
that early intervention with nonsteroidal anti-inflammatory
drugs (NSAIDs) is protective [53]. Furthermore, TNF inhi-
bition has been most successful in rheumatoid arthritis,
not so in multiple sclerosis and its eﬀect remains currently
to be fully assessed in PD [54]. TNF antagonists may not
be eﬀective as a treatment since they will only block one
mediator, that is, TNF, hence a more eﬀective approach
may be to generally downgrade microglial activation with
fluoxetine. In vivo and in vitro studies have shown fluoxetine
to reducemicroglial-mediated neurotoxicity and to be a good
neuroprotective agent [55].
Furthermore, during an inflammatory response fol-
lowing infection, interferon-γ is produced which activates
macrophages and increases expression of the P2RX7 [56].
Interferon gamma was not highly upregulated (fold change:
x1.36; P = 0.03) but only indications of receptor upreg-
ulation activity was revealed from our dataset interferon
gamma receptor 1 (IFNGR1; x1.55). Upregulation of P2X7
receptor was demonstrated in Alzheimer’s disease brain on
activated microglia and astrocytes around amyloid plaques
[46, 57]. In vivo studies demonstrated that amyloid-β triggers
increases in intracellular Ca2+, ATP release, IL-1β secretion,
and plasma membrane permeabilisation in microglia [58].
The substantia nigra contains the highest concentration of
microglia in the brain [59]. P2RX7 were recently investigated
in vivo using a rat model of PD and found to be mostly
expressed onmicroglia but also on some astrocytes. Blocking
with an antagonist oﬀered partial but significant protection
to striatal DA neurones but did not prevent neuronal loss
[60]. P2X7 receptor would be a potential candidate for
therapeutic intervention since the absence of the receptor
has been shown to reduce leukocyte function and the
inflammatory response [61]. Even if cell death is not fully
prevented it can oﬀer some protection.
4.3. NOS3 and Angiogenesis. Angiogenesis has already been
highlighted with other microarray studies. AGTR1 (angiot-
ensin II receptor, type 1), an angiotensin receptor was signif-
icantly downregulated in 6/8 microarray studies (Table 4).
The neuroprotective eﬀects of blocking the angiotensin
receptor 1 on oxidative stress or/and microglial activation
have recently been demonstrated in the MPTP model of
Parkinson’s disease [62] and have been recently reviewed
[63]. We would like to focus mainly on endothelial nitric
oxide synthase (eNOS aka NOS3; nitric oxide synthase 3
endothelial cell) which was nearly 2-fold upregulated (x1.91)
in PD. Many proteins within our dataset are known to
interact with NOS3 (Figure 4) and some gene products have
been validated with RT-PCR. Several proteins are known
to directly increase NOS3 such as heat shock protein 90
(HSP90AA1; x1.79), caveolin-1 (CAV1; x1.68), ELF1 (x1.55),
endoglin (ENG; x1.86), Kruppel-like factor 2 (KLF2; x1.6),
tumour necrosis factor (ligand) superfamily member 10
(TNFSF10; x1.86), dynamin 2 (DNM2; x1.69), endothelial
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cell adhesion molecule (ESAM; x2.28), actinin alpha 4
(ACTN4; x1.88), thrombospondin 1 (THBS1 aka TSP1;
x-3.08), and GATA binding protein 2 (GATA2; x2.13).
Increased levels of eNOS positive cells were found in the SN
of a MPTP-mouse model of PD [64]. Moreover, eNOS activ-
ity was shown to be reduced when inhibiting SCLCO2A1—a
prostaglandin transporter [65]. Endoglin, a transmembrane
glycoprotein which plays an important role in vascular integ-
rity and homeostasis, was significantly upregulated (x1.86).
In endothelial cells, endoglin is upregulated by hypoxia or
TGF-β stimulation and downregulated by TNF-α [66]. In-
creased expression of endoglin resulted in eNOS expression
[67], while endoglin expression is regulated by ELF1 [68].
ELF1 was upregulated in PD substantia nigra (x1.55) and
more interestingly was found upregulated (x1.38, P =
0.00802) in the peripheral blood of PD patients [20]. This
latter evidence shows a direct link between increased expres-
sion of a gene product in the peripheral blood and tissue
perhaps this gene would prove useful as a potential putative
biomarker. Finally, thrombospondin 1 part of the throm-
bospondin family is an angiogenesis inhibitor and blocks
NO-driven angiogenesis. Loss of TSP1 has been associated
in animals with increased circulating endothelial precursors,
endothelial cell proliferation, and migration [69]. THBS1
was significantly downregulated (x−3.08) hence resulting
in a loss of angiogenesis inhibition. Blocking NO-driven
angiogenesis would prove as a potential neuroprotective
therapeutic avenue to explore further in the parkinsonian
brain even though endothelial dysfunction may not solely be
due to disease but also due to levodopa toxicity [70].
4.4. Cytokines and Neuronal Development. TNFRSF14 (aka
HVEM, tumour necrosis factor receptor superfamily, mem-
ber 14 (herpes virus entry mediator)) was significantly
upregulated (x1.94) in PD. Expression levels have been
replicated (Table 3). Known mostly for facilitating HSV1
entry, this receptor has recently also been shown to play
a crucial role in the cell-survival system for lymphoid and
epithelial cells [71, 72] andmay be responsible for promoting
vascular inflammation [73]. Interestingly, increased levels
of the cytokine TNFSF14 (aka LIGHT) have been reported
in two independent microarray studies conducted on PD
blood samples [19, 20]. There are clear signs of genes
upregulated in blood and tissue and as with ELF1 (discussed
above), TNFSF14 could also be a potential disease biomarker.
Not specific to PD as it was also found upregulated in
amyotrophic lateral sclerosis (ALS) and Huntington’s disease
(HD) perhaps suggesting regional localised activity of this
receptor in the cervical spinal cord and basal ganglia
(manuscript submitted by Durrenberger et al.). Although
TNFSF14 has no known role in the CNS, a very recent
study has shown in cultured neurones that LIGHT/HVEM
signalling negatively regulated neurite outgrowth from
developing sensory neurones [74]. A better understanding of
LIGHT/HVEM signalling might prove beneficial for PD and
other motor neurones disorders.
Cerebellin 1 precursor (CBLN1; x-2.90) was significant-
ly downregulated in 5/8 microarray datasets including the
study on dopaminergic neurones (Table 4). Crbln1, belong-
ing to the C1q/tumour necrosis factor subfamily, has only
recently been identified as a new transneuronal cytokine
(neuromodulator) and was shown to be involved in synapse
formation [75]. It was demonstrated that chronic stimula-
tion of neuronal activity by elevating extracellular K(+) levels
or by adding kainate to generate kainate-induced seizures
decreased rapidly the expression of cbln1 mRNA in mature
cerebellar granule cells and that activity-induced reduction
was prevented by the addition of exogenous Cbln1 to culture
medium [76]. This paradigm could be tested in a PD animal
model to determine whether the addition of exogenous
Cbln1 could improve neuronal activity in PD.
5. Concluding Remarks
In summary, although the initiator of striatal DA neuronal
cell death remains to be determined based in our analysis,
this event does not remain without consequences. Extra-
cellular ATP, reactive astrocytes appear to be responsible in
the activation of microglia which in turn release proinflam-
matory cytokines contributing further to the parkinsonian
condition in the parenchyma. Our data is supportive of
a growing body of evidence suggesting that microglial
activation plays a key role in the progression of PDwith brain
rennin-angiotensin systems (RAS) as a key mechanism. In
addition to tackling oxidative stress pathways we also suggest
to reduce innate immunity activation via the manipulation
of the brain’s RAS so to enhance and support new neuronal
outgrowth. Interactions between these mechanisms as well
as perhaps the host’s ability to resolve inflammation deserve
further investigations
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